Ken Griffin Innate Pharma Sa Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Innate Pharma Sa stock. As of the latest transaction made, Citadel Advisors LLC holds 24,267 shares of IPHA stock, worth $42,952. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,267
Previous 11,853
104.73%
Holding current value
$42,952
Previous $21,000
104.76%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding IPHA
# of Institutions
10Shares Held
97.2KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY43.5KShares$77,0370.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny15.3KShares$27,1270.0% of portfolio
-
Ubs Group Ag9KShares$15,9310.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.98KShares$7,0350.01% of portfolio
-
Rhumbline Advisers Boston, MA675Shares$1,1940.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $141M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...